Literature DB >> 19939875

Harms associated with psychoactive substances: findings of the UK National Drug Survey.

Celia J A Morgan1, Leslie Muetzelfeldt, Mark Muetzelfeldt, David J Nutt, H Valerie Curran.   

Abstract

Nutt and colleagues' 'rational' scale to assess the harms of commonly used drugs was based on ratings by a panel of experts. This survey aimed to assess drug users' views of the harms of drugs using the same scale. As users' drug choices are not solely based on harms, we additionally assessed perceived benefits. The survey was hosted at http://www.nationaldrugsurvey.org. UK residents reported their experience of 20 commonly used substances; those with direct experience of a substance rated its physical, dependence-related and social harms as well as benefits. A total of 1501 users completed the survey. There was no correlation between the classification of the 20 drugs under the Misuse of Drugs Act and ranking of harms by users. Despite being unclassified substances, alcohol, solvents and tobacco were rated within the top ten most harmful drugs. There was a remarkably high correlation (r = 0.896) overall between rankings by users' and by experts. Ecstasy, cannabis and LSD were ranked highest by users on both acute and chronic benefits. These findings imply that users are relatively well informed about the harms associated with the drugs they use. They also suggest that the current UK legal classification system is not acting to inform users of the harms of psychoactive substances.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939875     DOI: 10.1177/0269881109106915

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  16 in total

1.  "I'm not afraid of those ones just 'cause they've been prescribed": perceptions of risk among illicit users of pharmaceutical opioids.

Authors:  Raminta Daniulaityte; Russel Falck; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2012-03-13

2.  Marijuana use and achievement of abstinence from alcohol and other drugs among people with substance dependence: a prospective cohort study.

Authors:  Mohammadali Mojarrad; Jeffrey H Samet; Debbie M Cheng; Michael R Winter; Richard Saitz
Journal:  Drug Alcohol Depend       Date:  2014-06-18       Impact factor: 4.492

Review 3.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

4.  Adverse drug-related effects among electronic dance music party attendees.

Authors:  Joseph J Palamar; Patricia Acosta; Austin Le; Charles M Cleland; Lewis S Nelson
Journal:  Int J Drug Policy       Date:  2019-07-23

Review 5.  Evidence-based Treatment Options in Cannabis Dependency.

Authors:  Lisa Walther; Andreas Gantner; Andreas Heinz; Tomislav Majić
Journal:  Dtsch Arztebl Int       Date:  2016-09-30       Impact factor: 5.594

6.  Enhancement drugs: are there limits to what we should enhance and why?

Authors:  Morten Hesse
Journal:  BMC Med       Date:  2010-08-03       Impact factor: 8.775

7.  Predictors of disapproval toward "hard drug" use among high school seniors in the US.

Authors:  Joseph J Palamar
Journal:  Prev Sci       Date:  2014-10

8.  Adverse psychosocial outcomes associated with drug use among US high school seniors: a comparison of alcohol and marijuana.

Authors:  Joseph J Palamar; Michael Fenstermaker; Dimita Kamboukos; Danielle C Ompad; Charles M Cleland; Michael Weitzman
Journal:  Am J Drug Alcohol Abuse       Date:  2014-08-29       Impact factor: 3.829

9.  Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.

Authors:  Dirk W Lachenmeier; Jürgen Rehm
Journal:  Sci Rep       Date:  2015-01-30       Impact factor: 4.379

10.  Psychedelics and mental health: a population study.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.